Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TevogenTVGN -8.08%10 FCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates TVGN with a GF Score™ of 10/100. The stock has 4 warning signs investors should review. Among 954 Biotechnology companies, Tevogen ranks worse than 104821.7% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Tevogen's Free Cash Flow for the
three
months ended in Mar. 2026 was $-2.73 Mil. Tevogen's Revenue for the
three
months ended in Mar. 2026 was $0.00 Mil. Therefore, Tevogen's FCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.
The historical rank and industry rank for Tevogen's FCF Margin % or its related term are showing as below:
TVGN's FCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -77.885 * Ranked among companies with meaningful FCF Margin % only.
The historical data trend for Tevogen's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Tevogen's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tevogen FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tevogen's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Tevogen's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tevogen (TVGN) has a FCF Margin % of 0.00% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Tevogen and its competitors. According to the industry distribution chart, Tevogen ranks #999999 out of 954 companies in the Biotechnology industry.
Is Tevogen's FCF Margin % too high?
Tevogen's current FCF Margin % is 0.00%. Based on the distribution chart, Tevogen ranks #999999 out of 954 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Tevogen has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Tevogen's FCF Margin % compare to ALLR and LGVN?
According to the Biotechnology industry distribution chart, Tevogen ranks #999999 out of 954 companies for FCF Margin %. This places Tevogen in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Tevogen and its competitors. Tevogen's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tevogen stock overvalued right now?
Tevogen (TVGN) has a current FCF Margin % of 0.00%. The current FCF Margin % is 0.00%. Tevogen's overall GF Score™ is 10/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Tevogen (TVGN), the current FCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The first clinical product of ExacTcell, TVGN 489, is initially being developed to fill a critical gap in COVID-19 therapeutics for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of chronic, lingering symptoms of the disease (Long COVID). Viruses, including COVID-19, hijack cellular machinery to transform infected cells into virus production plants.
10GF Score
Get the complete analysis for TVGN
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TVGN has been successfully added to your 
